Oxytocin

Overview

Oxytocin is a nonapeptide produced in the hypothalamus and released from the posterior pituitary. It contains a characteristic disulfide bridge between the cysteine residues at positions 1 and 6, forming a six-residue ring with a three-residue tail. Beyond its long-established peripheral roles, oxytocin has been the subject of a large experimental literature in which it is administered intranasally to human volunteers and its effects on social cognition, emotion recognition and related behavioural measures are assessed. This literature is notable for being unusually contested: early positive findings have been followed by null results, failed replications and meta-analyses that report much smaller effects than the initial studies suggested. Any honest summary has to present that disagreement rather than only the positive findings.

For research use only · Not FDA/EMA approved · Not for human consumption

Mechanism of Action

Oxytocin acts at the oxytocin receptor (OXTR), a G-protein coupled receptor, and shows cross-reactivity at vasopressin receptors owing to the close structural similarity between the two nonapeptides. Published research describes central effects mediated through oxytocin receptor populations in the amygdala, hippocampus and striatum, with proposed downstream modulation of dopaminergic and serotonergic signalling. A significant methodological question runs through the intranasal literature and is discussed openly in it: the extent to which intranasally administered oxytocin reaches central receptor populations at behaviourally relevant concentrations remains debated, and this uncertainty is one of the proposed explanations for the inconsistency of published behavioural results.

For research use only · Not FDA/EMA approved · Not for human consumption

Key Research Areas

• Intranasal administration and social cognition in healthy volunteers
• Facial emotion recognition paradigms
• Meta-analysis of effects in neurodevelopmental conditions
• Dose-response relationships in experimental administration
• Null and failed-replication findings as part of the published record

For research use only · Not FDA/EMA approved · Not for human consumption

Published Studies (4 cited)

For research use only · Not FDA/EMA approved · Not for human consumption

Dosage in Published Research

Published human experimental studies have most commonly administered oxytocin intranasally at 24 IU, with a substantial minority of studies using 12 IU, 32 IU or 40 IU, typically 30–45 minutes before behavioural testing. A 2025 systematic review specifically examined whether a dose-response relationship is discernible across this literature. Dosing varies considerably by paradigm and no standard research protocol exists. All figures are reported from published literature for reference purposes only.

For research use only · Not FDA/EMA approved · Not for human consumption

Storage & Handling

Store lyophilized powder at -20°C for long-term storage, protected from light and moisture. Once reconstituted, store at 2–8°C and use within 14 days. Oxytocin contains a disulfide bridge that is sensitive to reducing agents and to repeated freeze-thaw cycles. Handle under sterile laboratory conditions using appropriate PPE.

For research use only · Not FDA/EMA approved · Not for human consumption

Safety Profile (Literature Only)

In the published intranasal experimental literature, single-dose administration in healthy adult volunteers has generally been reported as well tolerated, with headache and nasal irritation among the effects noted. The published record concerns short-term experimental administration; effects of repeated or long-term administration in this setting are not well characterised in the literature. This compound is supplied for laboratory research use only and is not for human consumption.

For research use only · Not FDA/EMA approved · Not for human consumption